Entero Therapeutics Toekomstige groei
Future criteriumcontroles 0/6
Entero Therapeutics is forecast to grow earnings and revenue by 5.9% and 95.3% per annum respectively while EPS is expected to grow by 46.2% per annum.
Belangrijke informatie
5.9%
Groei van de winst
46.2%
Groei van de winst per aandeel
Biotechs winstgroei | 27.1% |
Inkomstengroei | 95.3% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 27 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
First Wave BioPharma announces pricing of $6.0 million public offering
Oct 07First Wave BioPharma extends selloff after announcing strategic shift
Sep 19First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase
Sep 07First Wave BioPharma announces 1-for-30 reverse stock split
Aug 25First Wave BioPharma to raise capital in convertible preferred stocks offering
Jul 15First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment
Oct 19AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study
Jun 07AzurRx BioPharma: An Assessment
May 02AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio
Jan 31Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | N/A | -42 | N/A | N/A | 1 |
12/31/2025 | N/A | -32 | N/A | N/A | 1 |
12/31/2024 | N/A | -11 | N/A | N/A | 1 |
6/30/2024 | N/A | -10 | -14 | -14 | N/A |
3/31/2024 | N/A | -6 | -14 | -13 | N/A |
12/31/2023 | N/A | -16 | -13 | -12 | N/A |
9/30/2023 | N/A | -16 | -15 | -15 | N/A |
6/30/2023 | N/A | -8 | -15 | -15 | N/A |
3/31/2023 | N/A | -9 | -17 | -17 | N/A |
12/31/2022 | N/A | -15 | -22 | -22 | N/A |
9/30/2022 | N/A | -22 | -33 | -23 | N/A |
6/30/2022 | N/A | -57 | -44 | -34 | N/A |
3/31/2022 | N/A | -65 | -45 | -35 | N/A |
12/31/2021 | N/A | -85 | -43 | -32 | N/A |
9/30/2021 | N/A | -92 | -32 | -32 | N/A |
6/30/2021 | N/A | -74 | -19 | -19 | N/A |
3/31/2021 | N/A | -66 | -15 | -15 | N/A |
12/31/2020 | N/A | -42 | -11 | -11 | N/A |
9/30/2020 | N/A | -25 | -9 | -9 | N/A |
6/30/2020 | N/A | -15 | -10 | -10 | N/A |
3/31/2020 | N/A | -16 | -13 | -13 | N/A |
12/31/2019 | N/A | -15 | -14 | -14 | N/A |
9/30/2019 | N/A | -18 | -14 | -14 | N/A |
6/30/2019 | N/A | -16 | -13 | -13 | N/A |
3/31/2019 | N/A | -15 | -12 | -11 | N/A |
12/31/2018 | N/A | -14 | -11 | -11 | N/A |
9/30/2018 | N/A | -12 | -10 | -10 | N/A |
6/30/2018 | N/A | -13 | -9 | -9 | N/A |
3/31/2018 | N/A | -12 | N/A | -8 | N/A |
12/31/2017 | N/A | -11 | N/A | -7 | N/A |
9/30/2017 | N/A | -14 | N/A | -7 | N/A |
6/30/2017 | N/A | -14 | N/A | -7 | N/A |
3/31/2017 | N/A | -15 | N/A | -5 | N/A |
12/31/2016 | N/A | -15 | N/A | -5 | N/A |
9/30/2016 | N/A | -10 | N/A | -3 | N/A |
6/30/2016 | N/A | -8 | N/A | -4 | N/A |
3/31/2016 | N/A | -7 | N/A | -4 | N/A |
12/31/2015 | N/A | -6 | N/A | -4 | N/A |
9/30/2015 | N/A | -6 | N/A | -4 | N/A |
6/30/2015 | N/A | -5 | N/A | -3 | N/A |
3/31/2015 | N/A | -3 | N/A | -2 | N/A |
12/31/2014 | N/A | -2 | N/A | -1 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: ENTO is forecast to remain unprofitable over the next 3 years.
Winst versus markt: ENTO is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: ENTO is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: ENTO is forecast to have no revenue next year.
Hoge groei-inkomsten: ENTO is forecast to have no revenue next year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if ENTO's Return on Equity is forecast to be high in 3 years time